We have developed a camera-based sensor for 24h automatic sea lice counting and biomass measurement. Our product solves the main challenges in high contrast underwater imagery of sea lice with deficient maintenance. We are looking for funding to take the effect to the next level, where approval of our solution in the industry and by authorities are key factors as well as the development of the organization.

24Nettbutikk is one of the leading e-commerce platforms in the Norwegian market. More than 1200 small and medium businesses currently use the platform to sell their products through digital channels. 24Nettbutikk focuses on developing strong partnerships and technical integrations with leading providers of services such as logistics, payments and marketing to offer a complete solution for our merchants at a competitive cost. We have a strong focus on our customer's success and work hard every day to ensure that customers experience a short time to value and continuous growth in sales volume.

We have developed a system for calculating and supplying Solcelle, and wind power for Scandinavia. In addition to this, we have obtained a license as a power supplier, so we can offer our customers both purchases and sales of green power. Why solar cells? Sun provides energy. As an energy source, the sun is unsurpassed. Every year, the earth receives 15,000 times more energy from the sun than the earth's population uses. Even in Norway, the sun provides 1,500 times more energy than what we use. Depending on where on the globe you are, the sun provides an amount of energy from 700 to over 2,200 kWh/m2 per year.

Iterate is an ecosystem for digital innovation, and we like to describe ourselves as a company that builds companies. We contribute from A-Z when building, starting with creating concepts based on key insights to launching and improving products whilst living in the marketplace. We find the right team and work toward the company culture that enables us to deliver value to our customers quickly. The key to achieving this is reinvesting all our profits in the ideas of our employees, or selected entrepreneurs. Five years into this strategy, we own shares in fifteen ventures; all of which are showing promising results. Our 70 designers, developers, and product managers just moved into new locations in the center of Oslo. 
Close collaboration with our customers is key to our success. They provide domain know-how, and we provide tools, strategies, and experts. Together we uncover the best way that connects your strategy and idea with the market needs. Our goal is to achieve minimum risk and give our customers the best possible starting point for scaling, on their own, or in continued collaboration.

The Founder Institute is the world’s premier startup launch program for talented entrepreneurs. If you are up to the challenge, our comprehensive step-by-step program will give you the structure, mentor support, and network of entrepreneurs you need to start an enduring company. Based in Silicon Valley and with chapters across 60 countries, the Founder Institute's mission is to "Globalize Silicon Valley" and build sustainable startup ecosystems worldwide.

Otivio’s main product, FlowOx™, is addressing chronic wounds with focus on peripheral arterial disease (PAD), which is a serious condition leading to pain, chronic wounds and in many cases amputation and mortality. The patient population is very large and increasing. There are limited adequate treatment options offered to the patients aside from surgical interventions. FlowOx™ is a non-invasive product intended for home use. Long-term patient testing in more than 50 patients documents increased blood flow, reduced pain and wound healing. FlowOx™ is CE marked. In fourth quarter 2017 had its commercial break-through through sales of FlowOx to public customers.

Oncoinvent AS is a privately held Norwegian company established in 2010. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The innovations being developed by Oncoinvent AS are a result of the extensive experience with the development of radionuclide-based cancer treatments of two of the founders, Dr. Roy H. Larsen and Professor of clinical oncology Øyvind S. Bruland. Larsen and Bruland are the inventors of the first FDA and EMA-approved alpha-emitting pharmaceutical product Xofigo® (Bayer AG), as well as of the beta-emitting radio-immunotherapeutic product candidate Betalutin® (Nordic Nanovector ASA). Oncoinvent's lead product candidate, Radspherin®, is a novel alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in body cavities. Radspherin® has been shown to cause a significant reduction in tumor cell growth. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be the treatment of peritoneal carcinomatosis. Clinical development will be conducted in collaboration with European and American clinical research centers.

AURA Biopharm AS was founded in 2016 by a team of scientists and drug developers with many years of experience in academia and major pharmaceutical companies and a proven track record of success in drug development. The emphasis of AURA is the development of novel and breakthrough therapies for unmet medical needs and orphan diseases and our slogan “A new opportunity for health” reflects AURA's mission to give a new opportunity to diseases in need of new and/or better therapies. The company operates virtually using a network of external collaborators (consultants, KOLs, CROs, CMOs etc).

Together with four Norwegian hospitals, we have developed the next generation hospital bed. A bed that prevents pressure ulcers, fall and reduce nurse load by removing heavy lifting and monitors the patients state, non intrusive. Have recieved contracts in Toronto that accelerates development, and secures uptake and sales if the clinical trial goes as planned.

Pridok AS er et Horten basert softwarefirma som har utviklet et nytt og moderne skybasert elektronisk pasientjournalsystem, Pridok EPJ på Microsoft Azure plattformen. Vi har tatt utgangspunkt i Helsedirektoratets kravspesifikasjon og lagt til ytterligere krav som vi har kartlagt.Pasientsikkerhet og kvalitetsikring av behandlingen er et stort fokusområde i Pridok EPJ. Nå kan legen for første gang bruke en EPJ-løsning uavhengig av plattform, enhet og som gir full mobilitet.Vi lar leger være leger uten at de må bruke tid på VPN, backup, servere etc.Flere hundre leger har forhåndsregistrert seg for løsningen vår som går i pilot våren 2017.

OK, Self-Storage Group consists of the brand's City Self-Storage and OK Minilager. We have more than 60 locations in Scandinavia. We aspire to be the leading company in tech in our industry. We have just closed funding from several investors, and we have an ambitious growth plan for the years to come.

Exabel is an artificial intelligence startup based in Oslo, Norway. Exabel’s mission is to synthesize the world’s information and learn how it evolves. We are developing a smart digital assistant software tool for professional investment managers. We are currently a team of 6 full-time employees, with diverse backgrounds; two mathematicians, three software engineers, and a business developer. Combined, we have strong experience with companies like Google, Medallia, Arctic Securities, Intelligent Trading, Microsoft, and Brain Corporation. We are located in Forskningsparken, by StartupLab. The company is well funded for several years of research, product development, and market launch.

Sereluna designs and sells its own menstrual underwear for the Norwegian market. We are the first menstrual underwear brand in Norway. Menstrual underwear has built in protection and is designed to be washed and reused for several years. Menstrual underwear completely replaces disposable protection like pads and tampons. The reason why Sereluna was created was to offer ladies in Norway a sustainable and more comfortable choice when they have their period. Our whole value chain is within Europe.

Precorn helps entrepreneurs commercialize their idea. By combining capital with active participation in the company, the entrepreneurs get the best conditions for success. What ideas we choose We invest in innovative ideas with a clear value proposition that is easy to communicate. Who we invest in We invest in enterprising, inspiring and goal-oriented people with values that coincide with ours. Currently looking for NOK 5 million in financing to complete the investment in our first SPV that contains three incredible startups

Zeabuz is a spin-off from the leading research community on autonomous vessels at NTNU in Trondheim. Our autonomy technology is field-proven for shortcuts across urban waterways, and we are now searching for long-term investors while preparing for market launch. Water used to be the main infrastructure for most cities in the world. While roads are filling up everywhere, much of the urban waters are have become highly underutilized. At Zeabuz we want to reverse this trend by introducing a technology platform that makes local waterborne transport an economically viable and sustainable option. Our mobility system, which comprises a combination of a network of small vessels, electric drive, and autonomous operation, is a truly scalable solution fit for many of the world’s urban areas. Enabling increased flow by utilizing available waterways will allow more people to travel by foot and bike and hence will reduce the need for road traffic and in the end reduce emissions of climate gasses. Another perspective is that dynamic utilization of waterways will reduce the need for new inflexible infrastructures such as roads and bridges, which saves both money, emissions from concrete production, and local footprint. The Zeabuz urban mobility system will be a compelling and attractive mobility solution for cities globally. Rough estimates have shown that there is a market for approx. 4000 Zeabuz-like ferries in the EU alone. Zeabuz aims to take a major share of this emerging market. The company is founded on the idea that passenger transport across urban waters is a highly suitable starting point for commercializing autonomous mobility. In this segment, risks are mitigated by low speeds and high physical margins which also allow us to focus on solving only a few problems at a time while still earning positive returns from the start. As the Zeabuz technology platform matures in this first segment, we will explore its scaling potential across several dimensions. This means we could branch out and adapt to new opportunities and market demand based on our solid foundation in autonomy, assurance, and mobility solutions. Our autonomy platform can be utilized to deliver Autonomy-as-a-Service which enables entries into new markets, new use cases, and an expansion to more complex operational domains. Zeabuz is now preparing for launching a commercial pilot in a Scandinavian city in 2022. Much of the financial structure required is already in place and will be triggered by the entry of a Lead Investor